Sign in
Companies / REGN vs VRTX

REGN vs VRTX: Regeneron Pharmaceuticals and Vertex Pharmaceuticals

Biotechnology
Compare more companies

Regeneron Pharmaceuticals (REGN) reported $14.3B in revenue against a 31.4% net margin, while Vertex Pharmaceuticals (VRTX) reported $12.0B at a 32.9% net margin, most recently.

MetricREGNVRTX
Revenue$14.3B$12.0B
Net Income$4.5B$4.0B
Gross Margin—86.2%
Operating Margin24.9%34.8%
EPS (Diluted)$41.48$15.32
Free Cash Flow$4.1B$3.2B
Total Debt$2.7B—
P/E Ratio18.6×29.6×
P/B Ration/m6.2×
Stock Price$910.75$542.69
Free: last 5 years
Fiscal yearFY2008 🔒FY2009 🔒FY2010 🔒FY2011 🔒FY2012 🔒FY2013 🔒FY2014 🔒FY2015 🔒FY2016 🔒FY2017 🔒FY2018 🔒FY2019 🔒FY2020 🔒FY2021FY2022FY2023FY2024FY2025
REGN Revenue•••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••$16.1B$12.2B$13.1B$14.2B$14.3B
VRTX Revenue•••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••$7.6B$8.9B$9.9B$11.0B$12.0B

More on REGN

More on VRTX

Other comparisons